3,302 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by Venturi Wealth Management LLC

Venturi Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 3,302 shares of the company’s stock, valued at approximately $60,000.

A number of other hedge funds have also modified their holdings of the company. New Covenant Trust Company N.A. purchased a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $28,000. EntryPoint Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $30,000. UMB Bank n.a. increased its stake in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA purchased a new position in shares of Teva Pharmaceutical Industries during the second quarter worth $48,000. Finally, Byrne Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the second quarter worth $52,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $16.44 on Friday. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The firm has a fifty day moving average of $17.81 and a 200 day moving average of $17.20. The firm has a market cap of $18.62 billion, a PE ratio of -19.34, a PEG ratio of 1.32 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a one year low of $8.64 and a one year high of $19.31.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. UBS Group raised their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Barclays boosted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.